10-Q: Amphastar Pharmaceuticals Q2 2026: Revenue Up, Costs Rise, FDA Warning Looms

Amphastar Pharmaceuticals reported a 5% increase in net revenues for Q2 2026, reaching $183.9 million, but faced higher costs and an FDA warning letter for its IMS subsidiary.

Summary

• Amphastar Pharmaceuticals reported net revenues of $183.9 million for the three months ended June 30, 2026, a 5% increase compared to $174.4 million in the same period of 2025.
• For the six months ended June 30, 2026, net revenues were $355.1 million, up 3% from $344.9 million in the prior year.
• Gross profit for the three months decreased by 8% to $93.5 million, with gross margin declining to 51% from 50% year-over-year.
• For the six-month period, gross profit decreased by 5% to $163.8 million, with gross margin falling to 46% from 50% year-over-year.
• Operating expenses increased significantly, with selling, distribution, and marketing expenses up 30% and general and administrative expenses up 30% for the quarter.
• Research and development expenses increased by 10% for the quarter and 22% for the six-month period.
• Net income for the three months ended June 30, 2026, was $30.3 million, a slight decrease from $31.0 million in the prior year.
• Net income for the six months ended June 30, 2026, was $36.8 million, a substantial decrease from $56.3 million in the prior year.
• The company's IMS subsidiary received an FDA warning letter in July 2026 related to cGMP violations, though it does not require a halt in product distribution.
• A $100 million milestone payment related to BAQSIMI sales is due in Q3 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, with revenue growth offset by increased costs and a significant FDA warning letter impacting operations.

Positives

• Net revenues increased by 5% to $183.9 million for the three months ended June 30, 2026, compared to the prior year.
• Net revenues increased by 3% to $355.1 million for the six months ended June 30, 2026, compared to the prior year.
• Launched Ipratropium Bromide HFA inhalation aerosol in April 2026.
• Continued marketing efforts for BAQSIMI contributed to an increase in unit volumes.
• Increased demand for epinephrine pre-filled syringe due to competitor shortages.
• Growth in Albuterol sales due to increased unit volumes.
• Increase in sales of recently launched products like Iron Sucrose and Teriparatide.
• Positive impact on sales from increased demand for Phytonadione and Sodium Bicarbonate due to supplier shortages.

Negatives

• Gross profit decreased by 8% to $93.5 million for the three months ended June 30, 2026.
• Gross margin decreased to 51% for the three months ended June 30, 2026, from 50% in the prior year.
• Gross profit decreased by 5% to $163.8 million for the six months ended June 30, 2026.
• Gross margin decreased to 46% for the six months ended June 30, 2026, from 50% in the prior year.
• Selling, distribution, and marketing expenses increased by 30% for the quarter.
• General and administrative expenses increased by 30% for the quarter.
• Research and development expenses increased by 10% for the quarter and 22% for the six-month period.
• Net income decreased to $30.3 million for the three months ended June 30, 2026, from $31.0 million in the prior year.
• Net income decreased to $36.8 million for the six months ended June 30, 2026, from $56.3 million in the prior year.
• Sales of BAQSIMI decreased by 3% for the quarter and 8% for the six-month period, primarily due to lower average selling prices.
• Sales of Glucagon decreased by 42% for the quarter and 49% for the six-month period due to increased competition and product shifts.
• The company's IMS subsidiary received an FDA warning letter in July 2026.
• A $100 million milestone payment related to BAQSIMI sales is due in Q3 2026.

Risks

• The FDA warning letter received by the IMS subsidiary could lead to further regulatory or legal action if deficiencies are not resolved to the FDA's satisfaction.
• Failure to resolve cGMP compliance issues at the IMS facility could materially adversely affect the company's business or sales of products manufactured by IMS.
• The company depends on a contract manufacturing organization for the supply of BAQSIMI, and any non-compliance with regulatory requirements could have a material adverse effect.
• Some raw materials and APIs may only be available from a limited number of sources, and establishing new suppliers can be time-consuming and costly.
• Potential for adverse application of environmental, health, and safety laws and regulations on operations.
• The company faces competition in the development and marketing of its products and product candidates.
• The company anticipates that sales of glucagon will continue to decline due to competitive dynamics.
• The company may see lower sales from its IMS subsidiary due to remediation efforts for the FDA warning letter.

Future Outlook

The company anticipates continued decline in glucagon sales due to competition and potential fluctuations in epinephrine and other product sales based on competitor supply. Remediation efforts for the FDA warning letter at the IMS facility may lead to lower sales from that subsidiary. Research and development expenses are expected to increase annually due to clinical trials for proprietary, insulin, and inhalation product candidates.

Management Comments

• We take the matters identified in the Warning Letter seriously.
• Aside from the use of additional resources and temporary suspension of one product in connection with the remediation plan, at this time, we do not anticipate a material adverse effect on our overall business operations and sales.
• We anticipate that sales of glucagon will continue to decline in the future due to competitive dynamics.
• We also anticipate that sales of epinephrine and other products will continue to fluctuate depending on the ability of our competitors to supply market demands.
• We may see lower sales from our IMS subsidiary, as we take steps to remediate an FDA warning letter at that facility, which could cause a slowdown in production.

Industry Context

StockSavvy.ai notes that Amphastar operates in a highly competitive biopharmaceutical market, facing challenges from both generic and branded competitors. The recent FDA warning letter highlights the critical importance of maintaining stringent manufacturing standards (cGMP) in this regulated industry, a factor that can significantly impact production, supply chain, and market access.

Comparison to Industry Standards

• The company's gross margin of 46% for the six months ended June 30, 2026, is within the typical range for generic pharmaceutical manufacturers, though it has seen a decline from the previous year.
• The increase in R&D expenses to 22% of net revenues for the six-month period reflects a common strategy in the biopharmaceutical industry to invest in pipeline development for future growth.
• The company's reliance on key customers like Cencora, McKesson, and Cardinal Health (representing 64% of accounts receivable and 69% of net revenues for the six months) is typical for pharmaceutical distributors, but also presents a concentration risk.
• The FDA warning letter issued to the IMS subsidiary is a significant event that requires careful monitoring, as such letters can lead to production halts or delays, impacting supply and revenue, a risk common to all pharmaceutical manufacturers.

Legal Proceedings

• A former employee initiated employment litigation with individual and class action claims for alleged violations of the California Labor Code, PAGA, wage and hour, and other state laws. The court ordered dismissal of individual and class claims, leaving only the PAGA claim.
• A former employee initiated employment litigation with individual and class action claims for alleged violations of the California Labor Code, wage and hour, and other state laws.
• A former employee initiated a class action litigation for alleged violations of the California Labor Code, PAGA, wage and hour, and other state laws.
• The company has accrued $1.0 million related to these employee litigations as of June 30, 2026.

Related Party Transactions

• License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (related party) for corticotropin compound, including an upfront payment of $2.0 million and potential milestone and royalty payments.
• Contract manufacturing agreements with Hanxin and its subsidiaries, recognizing $1.1 million in revenue for manufacturing services provided to Hanxin in the six months ended June 30, 2026.
• Contract research agreement with Hanxin for Recombinant Human Insulin Research Cell Banks, amended in March 2026 to focus on product candidate AMP-105, with an increase in total cost by approximately $0.6 million.
• Supply agreement with Nanjing Letop Biotechnology Co., Ltd. (related party) for chemical intermediates.
• Distribution agreement with Hong Kong Genreach Limited (wholly owned subsidiary of Hanxin) for Primatene MIST in the Greater China region and other territories.
• Distribution agreement with Nanjing Chengong Pharmaceutical Co., Limited (wholly-owned subsidiary of Hanxin) for BAQSIMI in the Greater China region, recognizing $0.1 million in revenue for the three months ended June 30, 2026.

Stakeholder Impact

• Shareholders may be impacted by the decrease in net income and the potential for stock price decline due to the FDA warning letter and pledged shares by executives.
• Employees may be affected by the ongoing remediation efforts at the IMS facility and potential impacts on operations.
• Customers may experience supply chain disruptions or product availability issues due to the FDA warning letter and ongoing remediation.
• Creditors may be concerned about the company's financial performance and the potential impact of the FDA warning letter on its ability to service debt, although the company states it is in compliance with debt covenants.

Next Steps

• Implement and continue corrective actions in response to the FDA warning letter at the IMS facility.
• Work with the FDA to address items identified in the Warning Letter.
• Continue to monitor and adjust chargeback and rebate estimates.
• Continue marketing efforts for BAQSIMI and other products.
• Pursue R&D for insulin and inhalation product candidates.
• Fund facility expansion with cash flows from operations.

Key Dates

Recommendation

While revenue growth is positive, the significant increase in operating expenses, decline in net income and gross margins, and the critical FDA warning letter for the IMS subsidiary introduce considerable uncertainty and risk. The company's ability to effectively remediate the cGMP issues and manage its cost structure will be key determinants of future performance. Therefore, a 'hold' recommendation is appropriate pending further clarity on the resolution of these issues.

Keywords

pharmaceuticals, generics, injectable products, inhalation products, intranasal products, API, BAQSIMI, FDA